Intuitive Surgical, Inc. vs Philip Morris International Inc. — how do they compare? Intuitive Surgical, Inc. trades at $415.78 (market cap $146.44B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 2.1× Intuitive Surgical, Inc.'s market cap, and Philip Morris International Inc. pays a 3.32% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Philip Morris International Inc. for 85 Days on average.
| ISRG | PM | |
|---|---|---|
Market Cap | $146.44B | $300.33B |
Volume | 1,895,430 | 3,935,700 |
Sector | Health | Consumer Staples |
52-Week High | $592.85 | $200.50 |
52-Week Low | $332.02 | $144.33 |
Typical Hold Time | 84 Days | 85 Days |
Enterprise Value | $141.22B | $343.44B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 2.63% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining impressive 28.45% net margins. Recent earnings beats and expansion into new markets like India and Japan support growth despite China headwinds. Technical indicators show the stock trading near pivot point resistance at $414 with support at $411.
ISRG presents a compelling growth story with dominant robotics positioning and expanding international footprint. The 17% selloff creates opportunity with 16% upside to consensus target of $480.78. Key risks include competitive pressures in robotic surgery and procedure growth normalization. Analyst consensus remains strongly bullish with 70% buy ratings, though valuation multiples remain elevated at P/E of 47.54.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →